Medarex - 500 Beiträge pro Seite

[pLeXt0r]

Wie gehts weiter?? Ist jetzt ein günstiger Einstieg, bei ca. 68€ oder ist da im lauf der nächsten wochen kaum noch luft nach oben??
Danke für eure Meinung mfG

[lukkk]

MEDAREX war gestern bei 82.50 , denke dass sich dieses noch diese woche wiederholt

[Chris8888]

Bin voll deiner Meinung,dem Chart zur Folge wird sich dieser Wert nach Freitag sicher wieder um die 80 $ aufhalten und denke auch das sich das nach nächstem Dienstag in den US weiter nach oben orientiert..KZ von 120 $ sehe ich nicht als abwegig,da Medx doch zu(!)stark an der Baisse verloren hat und dies nicht dem reellen Wert des Untenehmens entspricht!!!Dieser Eurokurs ist sicher noch ein Aufsprung wert,vor allem hinter dem hintergrund,das wir sicher nicht mehr vor der Rally so einen günstigen finden werden..

[PeterLustig]

die 38 Tage Linie und die 60 $ Hemmschwelle ist überschritten, ich denke auch, es geht weiter Richtung Norden

[WarrenB.]

Vergesst aber bitte nicht, dass Medarex noch vor wenigen Tagen auf 49€ war.Es handelt es sich bei dieser Aktie um einen sehr volatilen Wert.
Gruß Warren

[volkswagen]

Corixa and Medarex Form Alliance to Discover and Develop Therapeutic Monoclonal Antibodies
WEDNESDAY, JUNE 07, 2000 8:15 AM
- BusinessWire

SEATTLE and PRINCETON, N.J., Jun 7, 2000 (BW HealthWire) --

Multi-Product Collaboration to Target Autoimmune Diseases, Cancer
and Infectious Diseases

Corixa Corporation (Nasdaq:CRXA), a research and development-based biotechnology company, and Medarex, Inc. (Nasdaq:MEDX), a biopharmaceutical company, today announced a collaboration to discover and develop fully human monoclonal antibodies against selected targets from Corixa`s library of proprietary autoimmune disease, cancer and infectious disease antigens.

Corixa intends to contribute three targets initially and up to six or more targets a year during the term of the agreement. Medarex will contribute its HuMAb-Mouse(R) technology to the multi-year collaboration, targeted to generate, screen and characterize fully human monoclonal antibodies directed against Corixa`s antigens. Corixa, and in some cases Medarex, will then be responsible for determining whether the characterized antibodies have an immunotherapeutic effect in tissue culture experiments and in animal models of human disease.

When antibodies are jointly determined to be worthy of clinical investigation, Corixa and Medarex will hold a closed auction between the two parties for the rights to develop the specific antibody-based product. The company with the winning bid will pay the bid amount in cash to the other company and will be responsible at that point in time for all product development and commercialization expenses and decisions. The other company will receive future product development milestone payments and royalties on future product sales.

"We are pleased to be working with Medarex in a joint effort to develop fully human monoclonal antibody based therapeutics. We are impressed with Medarex`s growing technology base in the generation of fully human monoclonal antibodies," said Steven Gillis, Ph.D., chairman and chief executive officer of Corixa. "Our proprietary tumor antigen discovery efforts have led to identification of multiple, novel, cell-surface proteins that could prove useful as targets for therapeutic antibody development. In recent months we have intensified efforts in infectious disease antigen discovery and will continue to explore identification of antigens in autoimmune diseases where antibody therapy might prove beneficial in either stopping or reversing the disease process. The breadth of our antigen portfolio places us in the position of being able to develop antibodies with several partners. The addition of Medarex as a commercial collaborator represents another example of our Powered by Corixa(TM) approach targeting the presence of some element of Corixa`s technology in as many novel, immunotherapeutic products as possible."

"We look forward to a fruitful partnership that will combine Corixa`s expertise in antigen discovery with our HuMAb-Mouse technology," said Donald L. Drakeman, president and chief executive officer of Medarex. "This relationship could present Medarex with the opportunity to add to our own product development pipeline or benefit from products developed by Corixa. This partnership is another example of Medarex`s powerful technology base, which continues to evolve and offer our partners the benefits of high-affinity fully human antibodies."

The collaboration will be managed by a joint steering committee made up of representatives from both companies. The steering committee will be responsible for acceptance of Corixa antigens into the partnership, resource allocation, and determination of which resultant antibodies are available for auction.

About Corixa
Corixa is a research and development-based biotechnology company committed to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary vaccine components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals and diagnostics, targeting products that are Powered by Corixa(TM) technology with the goal of making its potential products available to patients around the world. Corixa was founded in 1994 and is headquartered in Seattle, Wash., with additional operations in Hamilton, Mont. and Redwood City, Calif. For more information, please visit Corixa`s website at www.corixa.com or call the company`s investor relations information line at 877/4CORIXA or 877/426-7492.

About Medarex
Medarex is a biopharmaceutical company developing monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. Medarex has assembled a broad platform of patented technologies for antibody discovery and development, including the HuMAb-Mouse and TC Mouse(TM)systems for the creation of high-affinity, fully human antibodies. Using standard, well proven laboratory techniques, scientists can produce these fully human antibodies in a matter of months. Medarex creates and develops fully human antibodies for itself and others, offering a full range of antibody development capabilities, including pre-clinical and clinical manufacturing services. For more information about Medarex visit its web site at www.medarex.com.

Forward-Looking Statements

[patera]

Hallo zusammen,

ich glaube das MEDAREX gerade vor der Wiederentdechung steht.
bin bei 68 mit 500 Stück rein
Auf steigendt Kurse 100 Euro sehe ich noch diesen Monat
für realistisch

Viel Erfolg Patera

[McBain]

Meine realistische Prognose ist 80-82 als heutigen Schlusskurs.

[janolo]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[COOLTOBS]

Mahlzeit !

Wie sicher sind eigentlich die Prognosen von Stock100.com ??

Die Prognose für die nächsten Tage lautet plus 21,7 %.

Schlußkurs für Ende nächster Woche : 88 $

Schön wär es ja !

Bitte um Meinungen !

Gruß,

COOLTOBS

[McBain]

Grade ein Seitwärtstrend. -0,66% aktuell in Berlin.
Müssen wohl auf Impulse aus dem Amiland hoffen.

[McBain]

Hi Cooltobs,
wäre schön wenn die Jungs von Stock100 recht haben. 21% Kursanstieg sind bei Medarex schon Standart kann man sagen.
Je nach dem was überm Teich passiert...Wie gesagt heute noch die 80. Langfristig kanns nur hoch gehen. Also kaufen und warten.
Rest kommt von alleine......

[Bakterie]

was heute noch passiert hängt von den US-Wirtschaftsdaten (Erzeugerpreise) ab. Sollte die NASDAQ steigen, wird auch MEDX steigen. Lieber langsam, aber stetig!